Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Matos

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trialsIgnacio Matos, Guillermo Villacampa, Cinta Hierro, et al.
The Lancet. Diabetes & Endocrinology|June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 studyVivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
Radiology|January 26, 2021
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid TumorsMarta Ligero, Alonso Garcia-Ruiz, Cristina Viaplana, et al.
British Journal of Cancer|May 18, 2016
A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropeniaPaula Jiménez Fonseca, Alberto Carmona-Bayonas, Ignacio Matos García, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trialsIgnacio Matos, Guillermo Villacampa, Cinta Hierro, et al.
The Lancet. Diabetes & Endocrinology|June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 studyVivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
Radiology|January 26, 2021
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid TumorsMarta Ligero, Alonso Garcia-Ruiz, Cristina Viaplana, et al.
British Journal of Cancer|May 18, 2016
A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropeniaPaula Jiménez Fonseca, Alberto Carmona-Bayonas, Ignacio Matos García, et al.
Pageof 4